Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haoxi Health Technology Limited (HAO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Haoxi files reports with the U.S. Securities and Exchange Commission, including annual reports on Form 20-F and current reports on Form 6-K, which together describe its online marketing business focused on healthcare advertiser clients in China.
In these filings, Haoxi explains how it generates revenue from one-stop online marketing solutions, including traffic acquisition from mainstream online media platforms, content production, data analysis, and advertising campaign optimization. The financial statements detail cost of revenue, which the company states is primarily driven by the purchase of online traffic from third-party media platforms and salaries and benefits for business operation staff, as well as selling, general and administrative, and research and development expenses related to its Bidding Compass online ads bidding analysis software.
Filings on Form 6-K also cover capital markets and corporate actions, such as follow-on public offerings, private placements of Class A ordinary shares, and the 1-for-25 reverse share split approved by shareholders. Other 6-K reports describe securities purchase agreements, the closing of private placements, and notices of shareholder meetings, including extraordinary general meetings.
On Stock Titan, each new Haoxi Health Technology Limited filing is captured from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in share capital, use of proceeds from offerings, and updates on listing status or corporate governance matters. Users can quickly review complex documents, locate information on share structure and financing transactions, and understand how Haoxi’s regulatory disclosures relate to its digital advertising operations in the healthcare sector.
Haoxi Health Technology Limited reported strong revenue growth but a steep increase in losses for the six months ended December 31, 2025. Net revenue rose to $33.83 million from $23.95 million, as the company expanded its online marketing services for healthcare advertisers and exited loss-making overseas operations, which helped lift gross margin to 4.72% from 2.01%.
Despite higher sales and improved margins, Haoxi recorded a net loss of $6.88 million, sharply wider than the $0.23 million loss a year earlier. The main drivers were a $6.02 million allowance for credit losses on prepaid advertising and third-party loans, and a $0.90 million impairment on digital intangible assets.
Operating cash outflow was $2.27 million, and the company invested $4.50 million in a convertible bond, partly funded by equity. Haoxi raised $4.93 million net from financing, including follow-on share offerings and warrant-related share issuances, ending the period with $6.80 million in cash and $15.96 million in shareholders’ equity. Management believes current liquidity covers at least 12 months of needs but acknowledges continued negative operating cash flows as it scales.
Haoxi Health Technology Limited reported a change in its independent auditor. The audit committee dismissed Wei, Wei & Co., LLP as the company’s independent registered public accounting firm, effective April 3, 2026, and appointed HCL, PLLC as the new independent auditor, also effective April 3, 2026.
The company states that during the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period, the former auditor issued no adverse opinions or qualifications, had no disagreements on accounting or auditing matters, and no “reportable event” occurred. The company also confirms it did not consult HCL, PLLC on accounting or audit issues before the engagement.
Haoxi Health Technology Ltd director and Chief Operating Officer Xu Lei LX reported their holdings in the company. The Form 3 filing shows direct ownership of 214,400 Class A ordinary shares of Haoxi Health Technology Ltd, reflecting the executive’s initial reported equity position in the issuer.
Haoxi Health Technology Ltd director Su Changmao has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing does not report any stock transactions, share holdings, or derivative positions in the provided data for this reporting person.
Haoxi Health Technology Ltd director and CEO Fan Zhen has filed an initial statement of beneficial ownership. The filing reports direct ownership of 690,800 Class B ordinary shares, par value US$0.0025 each, as of March 18, 2026. The document does not show any new purchases or sales, but establishes Fan Zhen’s existing equity stake in the company.
Haoxi Health Technology Ltd officer Li Dongxue, the company’s Chief Financial Officer, filed an initial Form 3 reporting beneficial ownership. The data provided shows no reportable transactions, holdings, or derivative positions, indicating this is a baseline regulatory disclosure rather than a trading event.
Haoxi Health Technology Ltd director Hu Chuanjie has filed an initial Form 3 insider report. The filing identifies him as a director, not an officer or ten percent owner of Haoxi Health Technology Ltd. The data provided shows no reported transactions, derivative positions, or holdings entries at this time.
Haoxi Health Technology Ltd director Liu Jia has filed an initial insider ownership report on Form 3. The filing identifies Liu Jia as a director of the company and, in the provided data, shows no reported transactions, share purchases or sales, and no listed derivative positions.
Haoxi Health Technology Limited reported a change in its board of directors. On March 6, 2026, director Jianbing Zhang resigned from the board for personal reasons, and the company stated that his resignation did not involve any disagreement over operations, policies, or practices.
The board appointed Chuanjie Hu as a new director effective the same day and determined he meets the “independence” requirements of Nasdaq and Rule 10A-3. Mr. Hu will chair the nominating and corporate governance committee and serve on the compensation and audit committees, and will not receive compensation for his board service.
Haoxi Health Technology Limited has terminated its at-the-market equity offering program with Aegis Capital Corp. The program had allowed the company to offer and sell up to $80 million of Class A ordinary shares under an effective Form F-3 shelf registration and related prospectus supplement.
Haoxi and Aegis entered into a mutual termination agreement effective February 7, 2026, ending the sales agreement and related arrangements. The company reports that it did not sell any Class A ordinary shares under this at-the-market program before it was terminated.